Category - Press releases

12
Jul

Accera Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio

BOULDER, Colo. and SEOUL, South Korea, July 11, 2017 – Accera, Inc. and DuChemBio Co. Ltd announced today that the companies have entered into a strategic partnership and exclusive licensing agreement whereby DuChemBio will obtain rights to develop, obtain regulatory approval and commercialize products in South Korea using Accera’s medium chain triglyceride technology. Accera, a …

4
May

Accera Appoints Dr. Judith Walker as Chief Medical Officer

– Dr. Walker takes the clinical leadership role in Accera’s Phase 3 Alzheimer’s disease program – BOULDER, Colo., May 3, 2017 – Accera, Inc., a leading central nervous system (CNS) therapeutics company, today announced the appointment of Judith Walker, M.D., F.R.C.P.(C), as Chief Medical Officer. Dr. Walker joins Accera from QuintilesIMS where she held the …

28
Feb

Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease

-Bioavailability of the drug was suboptimal- -New drug formulation addressing bioavailability has been developed and Accera is now finalizing next steps-   BOULDER, Colo., Feb. 28, 2017 — Accera, Inc., a leading CNS therapeutics company, today announced results of the AC-1204 Phase 3 study for the treatment of mild-to-moderate Alzheimer’s disease. Patients treated with AC-1204 …

30
Nov

Beyond the Failed Beta Amyloid Hypothesis

Accera’s Senior Medical Advisor, Michael Gold, M.D., to Moderate with Presentations by Russell Swerdlow, M.D., and Eugenia Trushina, Ph.D.  Boulder, Colo., Nov. 29, 2016 – Several leading Alzheimer’s disease experts will participate in a webinar hosted by Accera, Inc. at 11 a.m. EST on December 6 in advance of the 9th Annual International Conference on …

26
Sep

Accera to Present at Upcoming Healthcare and Investor Conferences

Boulder, Colo., Sept. 26, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced that the company will present at the following upcoming investor conferences: 16th Annual Biotech in Europe Forum: Dr. Charles Stacey, president and CEO, will present an overview of the company on Tuesday, September 27, …

8
Sep

Accera Appoints Jeffrey Cummings and Bruno Vellas to Scientific Advisory Board

BOULDER, Colo., Sept. 8, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced the appointment of Jeffrey L. Cummings, M.D., Sc.D. and Bruno Vellas, M.D., Ph.D. to the company’s Scientific Advisory Board. “As we progress toward Phase 3 data from the NOURISH AD study later this year …

2
Aug

Accera Appoints C. Evan Ballantyne as Chief Financial Officer

BOULDER, Colo., Aug. 2, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced the appointment of C. Evan Ballantyne as chief financial officer. “Evan brings to Accera over 30 years of financial experience with a strong emphasis in healthcare and drug development in both public and private …

12
May

Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for Alzheimer’s Disease Treatment

  BOULDER, Colo., May 12, 2016 /PRNewswire/ — Accera, Inc. today announced that it has completed enrollment of the NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of mild to moderate Alzheimer’s disease. The company expects to report top-line data in December. In conjunction with this, Accera is finalizing plans for a second …

10
Mar

Accera to Present at BIO Asia International Conference

CEO Charles Stacey to Discuss Global Clinical Trial Design as Part of a Panel Discussion   BROOMFIELD, Colo., March 10, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced that Dr. Charles Stacey, President and CEO, will present at the 13th Annual BIO Asia International Conference at …

8
Mar

Accera Appoints Ernest Wong, Ph.D., as Head of Corporate Development

Dr. Wong to Bring Over 15 Years of Experience in Pharmaceutical Business Development to the Company   BROOMFIELD, Colo., March 8, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced the appointment of Ernest Wong, Ph.D., MBA, as vice president of corporate development. Dr. Wong has over …

Page 1 of 4
X